Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

5-year Follow-up of the BETADOSE Trial: Non-inferiority of a 50% Dose Reduction of Antenatal Betamethasone Therapy on the Neurodevelopment of Children Born Before 32 Weeks of Gestation.

NCT04021485 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT04021485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04021485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
5-year Follow-up of the BETADOSE Trial: Non-inferiority of a 50% Dose Reduction of Antenatal Betamethasone Therapy on the Neurodevelopment of Children Born Before 32 Weeks of Gestation.
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Not applicable
Overall status
Completed
Start date
March 23, 2022
Completion date
September 9, 2025
Enrollment
386 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

premature childbirth